Use of Digital Twins in a Phase 2a Trial to Predict Disease-Progression of Participants with Mild-to-Moderate AD Supports Early Signals of Efficacy
Time: 2:00 pm
day: Conference Day One - Track Three
Details:
- Machine learning-generated digital twins of disease progression which can be seamlessly integrated across different stages of clinical development
- In this study, we demonstrate the utility of digital twins in a Phase 2a trial of REM0046127, a small molecule designed to restore the integrity of septin filaments in neurons affected by Alzheimer’s disease
- Digital twins validated the preliminary results on tau pathology biomarkers, providing valuable additional evidence to support advancement of the clinical program
